R
ReadCoor
ReadCoor is pioneering panomic spatial sequencing
About ReadCoor
ReadCoor is a biotechnology startup that has developed a unique platform for gene analysis. The company's technology uses a method called padlock probe rolling circle amplification chemistry, which is a highly sensitive and specific way of identifying and analyzing genes. This method allows for high sensitivity across a broad range of gene expression, including those that are low expressing or highly degraded. It also has the ability to distinguish between similar genes, such as isoforms.
The company's technology works in four steps. First, the probe arms must stably hybridize to their target gene. If only one arm hybridizes, the probe is unstable and will be washed off. The probes also contain a gene-specific barcode sequence that is used to generate a unique optical signature of each gene. Second, only when both probe arms are stably hybridized to the target with a perfect match does proximal probe ligation occur. Third, only ligated probes are amplified, which enriches for true target recognition events and suppresses off-target events. Finally, the amplified products in the samples undergo successive rounds of fluorescent probe hybridization, imaging, and removal. An optical signature specific to each gene is generated.
ReadCoor's clients are likely to be in the scientific and medical research fields, where gene analysis is crucial. The company operates in the biotechnology market and its business model is likely based on selling its technology and services to these clients. It makes money by providing a unique, highly sensitive and specific method of gene analysis.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 58.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2020 | $350M | $350M | 10X Genomics | — |
| SERIES BOther financing | Jan 2020 | $27M | $108M | Pavilion Capital Partners · Decheng Capital | — |
Growth signals
Latest recorded traffic for ReadCoor is 850 monthly website visits, down 77.6% over the last three months. ReadCoor's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Silicon Valley Community Foundation
Chan Zuckerberg Initiative
Series A5 investors entered at this stage
Decheng Capital
Lilly Asia Ventures
Vivo Capital- HWHansjörg Wyss
Pavilion Capital Partners
Other known investors1 additional known investor
10X Genomics
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ReadCoor on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ReadCoor’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







